Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Study of a Combination of FCX-013 (Genetically-Modified Autologous Human Dermal Fibroblasts) Plus Veledimex for the Treatment of Moderate to Severe Localized Scleroderma (Morphea)

Next Previous
Search
Trial Profile

A Phase 1/2 Study of a Combination of FCX-013 (Genetically-Modified Autologous Human Dermal Fibroblasts) Plus Veledimex for the Treatment of Moderate to Severe Localized Scleroderma (Morphea)

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 25 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs FCX-013 (Primary) ; Veledimex (Primary)
  • Indications Circumscribed scleroderma
  • Focus Adverse reactions
  • Sponsors Castle Creek Pharmaceuticals

    • Most Recent Events

    • 20 May 2022 Status changed from recruiting to discontinued.
    • 21 Mar 2022 Planned primary completion date changed from 1 Mar 2022 to 1 Jun 2022.
    • 26 Jan 2021 Planned End Date changed from 1 Mar 2021 to 1 Jan 2036.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top